daclizumab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4953 152923-56-3

Description:

MoleculeDescription

Synonyms:

  • zinbryta
  • daclizumab
  • zenapax
An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
5 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 26, 1999 EMA
Dec. 10, 1997 FDA HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2269.41 35.50 406 5370 4276 46676010
Transplant rejection 1890.32 35.50 391 5385 9205 46671081
Ovarian cyst 1582.90 35.50 362 5414 13725 46666561
Acne 1468.29 35.50 364 5412 19555 46660731
Alopecia 887.94 35.50 419 5357 161995 46518291
Sleep disorder due to general medical condition, insomnia type 620.01 35.50 141 5635 5108 46675178
Liver function test abnormal 346.75 35.50 150 5626 46337 46633949
Multiple sclerosis relapse 250.19 35.50 116 5660 42009 46638277
Kidney transplant rejection 139.56 35.50 41 5735 4077 46676209
Condition aggravated 127.94 35.50 154 5622 244898 46435388
Rheumatoid arthritis 123.81 35.50 150 5626 240065 46440221
Pneumonia 119.89 35.50 186 5590 376134 46304152
Loss of personal independence in daily activities 107.18 35.50 74 5702 57109 46623177
Cytomegalovirus infection 104.51 35.50 49 5727 18095 46662191
Incorrect route of product administration 78.47 35.50 39 5737 16344 46663942
Pain 71.06 35.50 171 5605 476777 46203509
Product use issue 70.80 35.50 72 5704 94572 46585714
Overdose 66.32 35.50 72 5704 101907 46578379
Lymphocele 45.13 35.50 12 5764 826 46679460
Encephalitis autoimmune 41.64 35.50 12 5764 1112 46679174
Multiple sclerosis 39.28 35.50 29 5747 24762 46655524
Immune-mediated adverse reaction 37.43 35.50 8 5768 214 46680072
Drug ineffective 36.84 35.50 173 5603 677665 46002621

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 243.63 26.21 85 2257 23589 29926547
Transplant rejection 101.92 26.21 35 2307 9171 29940965
Multiple sclerosis relapse 100.00 26.21 36 2306 10826 29939310
Lymphocele 99.26 26.21 23 2319 1437 29948699
Kidney transplant rejection 69.50 26.21 25 2317 7484 29942652
Complications of transplanted kidney 54.89 26.21 18 2324 4083 29946053
Ureteric stenosis 46.04 26.21 12 2330 1219 29948917
Sepsis 41.61 26.21 54 2288 146341 29803795
Blood creatinine increased 32.86 26.21 38 2304 91337 29858799
Autoimmune haemolytic anaemia 31.94 26.21 12 2330 4047 29946089
Urinary tract infection 28.78 26.21 32 2310 73627 29876509
BK virus infection 27.57 26.21 11 2331 4353 29945783

Pharmacologic Action:

SourceCodeDescription
ATC L04AC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000010279 Interleukin 2 Receptor Antagonists
FDA MoA N0000175621 Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC N0000175622 Interleukin-2 Receptor Blocking Antibody
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Renal transplant rejection indication 236570004
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-2 receptor Membrane receptor ANTIBODY BINDING Kd 8 IUPHAR DRUG LABEL

External reference:

IDSource
D03639 KEGG_DRUG
4021083 VUID
N0000148541 NUI
4021083 VANDF
C0663182 UMLSCUI
CHEMBL1201605 ChEMBL_ID
DB00111 DRUGBANK_ID
D000077561 MESH_DESCRIPTOR_UI
6880 IUPHAR_LIGAND_ID
7164 INN_ID
CUJ2MVI71Y UNII
1795335 RXNORM
11508 MMSL
241453 MMSL
4529 MMSL
d04262 MMSL
007284 NDDF
109133001 SNOMEDCT_US
386977009 SNOMEDCT_US

Pharmaceutical products:

None